About DiscGenics

DiscGenics is a privately held, clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions suffering from the debilitating effects of back pain. Our first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with degenerative disc disease (DDD).

Current openings